## Lantheus Holdings, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands, except per share data – unaudited)

**Three Months Ended** 

	June 30, 2020					June 30, 2019							
	GAAP		A	djustments	Non-GAAP Adjusted			GAAP		Adjustments		Non-GAAP Adjusted	
Revenues	\$	66,010			\$	66,010	\$	85,705			\$	85,705	
Cost of goods sold (a)		40,162		(1,698)		38,464		41,132		(984)		40,148	
Gross profit		25,848		1,698		27,546		44,573		984		45,557	
Operating expenses													
Sales and marketing (b)		6,305		(453)		5,852		10,948		(512)		10,436	
General and administrative (c)		20,670		(10,908)		9,762		13,293		(1,889)		11,404	
Research and development (b)		4,418		(431)		3,987		5,795		(742)		5,053	
Total operating expenses		31,393		(11,792)		19,601		30,036		(3,143)		26,893	
Operating (loss)		(5,545)		13,490		7,945	·	14,537		4,127		18,664	
Interest expense		1,914		_		1,914		4,543		_		4,543	
Loss on extinguishment of debt		_		_		_		3,196		(3,196)		_	
Other income		(756)		_		(756)		(1,312)		_		(1,312)	
(Loss) income before income taxes	' <u></u>	(6,703)		13,490		6,787		8,110		7,323		15,433	
Income tax expense (d)		309		1,940		2,249		1,698		2,852		4,550	
Net (loss) income	\$	(7,012)	\$	11,550	\$	4,538	\$	6,412	\$	4,471	\$	10,883	
Net (loss) income per common share - diluted	\$	(0.16)			\$	0.10	\$	0.16			\$	0.27	
Weighted-average common shares outstanding - diluted (e)		43,135		168		43,303		40,239				40,239	
Depreciation expense	\$	2,745		_	\$	2,745	\$	2,480			\$	2,480	
Amortization expense	\$	927		_	\$	927	\$	451			\$	451	

- (a) Includes stock and incentive plan compensation, amortization of acquired intangible assets and integration costs.
- (b) Includes stock and incentive plan compensation and integration costs.
- (c) Includes stock and incentive plan compensation, acquisition-related costs, integration costs and other non-recurring charges.
- (d) The income tax effect of the adjustments between GAAP net income (loss) and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.
- (e) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP net loss position.

## Lantheus Holdings, Inc.

## **Reconciliation of GAAP to Non-GAAP Financial Measures (Continued)**

(in thousands, except per share data – unaudited)

#### Six Months Ended

		June 30, 2020						June 30, 2019					
	GAAP		A	djustments	nents Non-GAAP Adjusted		GAAP		Adjustments		Non-GAAP Adjusted		
Revenues	\$	156,714			\$	156,714	\$	172,215			\$	172,215	
Cost of goods sold (a)		92,864		(10,088)		82,776		83,558		(1,884)		81,674	
Gross profit		63,850		10,088		73,938		88,657		1,884		90,541	
Operating expenses													
Sales and marketing (b)		16,435		(706)		15,729		21,345		(976)		20,369	
General and administrative		37,369		(16,327)		21,042		25,882		(3,490)		22,392	
Research and development (b)		8,466		(820)		7,646		10,724		(1,009)		9,715	
Total operating		62,270		(17,853)		44,417		57,951	_	(5,475)		52,476	
Operating income		1,580		27,941		29,521		30,706		7,359		38,065	
Interest expense		3,860		_		3,860		9,135		_		9,135	
Loss on extinguishment of		_		_		_		3,196		(3,196)		_	
Other income		(1,106)				(1,106)		(2,499)		_		(2,499)	
(Loss) income before income taxes		(1,174)		27,941		26,767		20,874		10,555		31,429	
Income tax expense (d)		2,501		5,446		7,947		4,513		4,795		9,308	
Net (loss) income	\$	(3,675)	\$	22,495	\$	18,820	\$	16,361	\$	5,760	\$	22,121	
Net (loss) income per common share - diluted	\$	(0.09)		_	\$	0.45	\$	0.41			\$	0.55	
Weighted-average common shares outstanding - diluted (e)		41,284		418		41,702		40,064				40,064	
Depreciation expense	\$	5,726			\$	5,726	\$	5,029			\$	5,029	
Amortization expense	\$	1,319			\$	1,319	\$	902		_	\$	902	

- (a) Includes stock and incentive plan compensation, amortization of acquired intangible assets, integration costs and impairment of long-lived assets.
- (b) Includes stock and incentive plan compensation and integration costs.
- (c) Includes stock and incentive plan compensation, acquisition-related costs, integration costs and other non-recurring charges.
- (d) The income tax effect of the adjustments between GAAP net income (loss) and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.
- (e) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP net loss position.

## Lantheus Holdings, Inc.

#### **Reconciliation of GAAP to Non-GAAP Financial Measures**

(in thousands, except per share data – unaudited)

#### **Three Months Ended**

		March 31, 2020 June 30, 2020				
	GAAP	Adjustments	Non- GAAP Adjusted	GAAP	Adjustments	Non- GAAP Adjusted
Revenues	\$90,704	\$ —	\$90,704	\$66,010		\$66,010
Cost of goods sold (a)	52,702	(8,390)	44,312	40,162	(1,698)	38,464
Gross profit	38,002	8,390	46,392	25,848	1,698	27,546
Operating expenses						
Sales and marketing (b)	10,130	(253)	9,877	6,305	(453)	5,852
General and administrative (c)	16,699	(5,419)	11,280	20,670	(10,908)	9,762
Research and development (b)	4,048	(389)	3,659	4,418	(431)	3,987
Total operating	30,877	(6,061)	24,816	31,393	(11,792)	19,601
Operating income	7,125	14,451	21,576	(5,545)	13,490	7,945
Interest expense	1,946	_	1,946	1,914	_	1,914
Other income	(350)	_	(350)	(756)		(756)
Income before income	5,529	14,451	19,980	(6,703)	13,490	6,787
Income tax expense (d)	2,192	3,506	5,698	309	1,940	2,249
Net income (loss)	\$ 3,337	\$ 10,945	\$14,282	\$(7,012)	\$ 11,550	\$ 4,538
Net income (loss) per common share - diluted	\$ 0.08		\$ 0.36	\$ (0.16)		\$ 0.10
Weighted-average common shares outstanding - diluted <sup>(e)</sup>	40,102		40,102	43,135	168	43,303
5	Φ 2 001		Φ 2 001	Φ 2.745		<b>A. 2.74</b>
Depreciation expense	\$ 2,981		\$ 2,981	\$ 2,745		\$ 2,745
Amortization expense	\$ 392		\$ 392	\$ 927		\$ 927

- (a) Includes stock and incentive plan compensation, amortization of acquired intangible assets, integration costs and impairment of long-lived assets.
- (b) Includes stock and incentive plan compensation and integration costs.
- (c) Includes stock and incentive plan compensation, acquisition-related costs, integration costs and other non-recurring charges.
- (d) The income tax effect of the adjustments between GAAP net income (loss) and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.
- (e) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP net loss position.

# Lantheus Holdings, Inc. Supplemental Revenue Information

(unaudited)

	Mor	nth Ended Ap	ril 30,	Mon	th Ended Ma	ay 31,	Month Ended June 30,			
(in thousands)	2020	2019	Change %	2020	2019	Change %	2020	2019	Change %	
U.S.										
DEFINITY	\$ 8,483	\$ 19,119	(55.6)%	\$ 13,144	\$ 17,370	(24.3)%	\$ 17,917	\$ 16,977	5.5 %	
TechneLite	4,213	5,134	(17.9)%	4,833	4,923	(1.8)%	6,545	6,808	(3.9)%	
Other nuclear	2,034	2,913	(30.2)%	1,287	3,623	(64.5)%	2,483	2,591	(4.2)%	
Rebates and allowances	(735)	(1,446)	(49.2)%	(1,199)	(1,419)	(15.5)%	(1,606)	(1,403)	14.5 %	
Total US revenues	13,995	25,720	(45.6)%	18,065	24,497	(26.3)%	25,339	24,973	1.5 %	
International				_					_	
DEFINITY	210	472	(55.5)%	270	348	(22.4)%	341	343	(0.6)%	
TechneLite	929	1,180	(21.3)%	1,169	1,310	(10.8)%	1,220	751	62.5 %	
Other nuclear	1,265	2,055	(38.4)%	1,579	1,820	(13.2)%	1,629	2,244	(27.4)%	
Rebates and allowances	_	(1)	(100.0)%	_	(7)	(100.0)%	(1)	_	100.0 %	
Total International revenues	2,404	3,706	(35.1)%	3,018	3,471	(13.1)%	3,189	3,338	(4.5)%	
Worldwide				_						
DEFINITY	8,693	19,591	(55.6)%	13,414	17,718	(24.3)%	18,258	17,320	5.4 %	
TechneLite	5,142	6,314	(18.6)%	6,002	6,233	(3.7)%	7,765	7,559	2.7 %	
Other nuclear <sup>(a)</sup>	3,299	4,968	(33.6)%	2,866	5,443	(47.3)%	4,112	4,835	(15.0)%	
Rebates and allowances	(735)	(1,447)	(49.2)%	(1,199)	(1,426)	(15.9)%	(1,607)	(1,403)	14.5 %	
Total revenues <sup>(b)</sup>	\$ 16,399	\$ 29,426	(44.3)%	\$ 21,083	\$ 27,968	(24.6)%	\$ 28,528	\$ 28,311	0.8 %	

<sup>(</sup>a) Includes Progenics revenue of \$1.0 million in the month ended June 30, 2020.

<sup>(</sup>b) Worldwide Total revenues declined 2.8% in the month ended June 30, 2020 excluding Progenics revenue.